Controversial Alzheimer’s Drug Faces Critical Test Before F.D.A. Panel

By BY PAM BELLUCK from NYT Health If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer’s treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline. https://ift.tt/3jZ7hgp